Skip to main content
Top
Published in: Current Infectious Disease Reports 4/2011

01-08-2011

West Nile Virus Neuroinvasive Disease

Author: Roberta L. DeBiasi

Published in: Current Infectious Disease Reports | Issue 4/2011

Login to get access

Abstract

West Nile virus (WNV), first recognized in North America in 1999, was responsible for the largest arboviral epidemic of human encephalitis in history and continues to be the most frequent cause of epidemic meningoencephalitis in North America. WNV neuroinvasive disease (WNND) occurs in fewer than 1% of infected individuals, with presentations including aseptic meningitis, encephalitis, and poliomyelitis. Between 1999 and 2009, over 12,000 cases of WNND were reported in the United States, with the peak annual incidence occurring in epidemics of 2002 and 2003. In this review, we first summarize the epidemiology of WNV over the past decade and the salient clinical features of WNND, including a discussion of laboratory and radiographic findings, risk factors, morbidity, and mortality. In addition, we review recent progress in our understanding of virus and host determinants of the pathogenesis of WNND, as well as the prospects for the development of specific therapeutic targets.
Literature
1.
go back to reference Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.PubMedCrossRef Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.PubMedCrossRef
2.
go back to reference Hayes EB, Komar N, Nasci RS, et al. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167–73.PubMed Hayes EB, Komar N, Nasci RS, et al. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167–73.PubMed
3.
go back to reference •• Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease - United States, 1999–2008. MMWR Surveill Summ. 2010;59(2):1–17. This is the most up-to-date summary on incidence rates for WNND over the 10-year period of WNV circulation in North America following first emergence, including incidence rates by age groups and top states for reported cases. The discussion of stability in incidence rates between 2004 and 2007 is suggestive of a potential endemic level of WNV transmission. PubMed •• Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease - United States, 1999–2008. MMWR Surveill Summ. 2010;59(2):1–17. This is the most up-to-date summary on incidence rates for WNND over the 10-year period of WNV circulation in North America following first emergence, including incidence rates by age groups and top states for reported cases. The discussion of stability in incidence rates between 2004 and 2007 is suggestive of a potential endemic level of WNV transmission. PubMed
4.
go back to reference • Centers for Disease Control (CDC). West Nile virus activity - United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(25):769–72. This is the most up-to-date single-year summary of WNV activity (including WNND), including the lowest incidence rate since the appearance of WNV in North America. • Centers for Disease Control (CDC). West Nile virus activity - United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(25):769–72. This is the most up-to-date single-year summary of WNV activity (including WNND), including the lowest incidence rate since the appearance of WNV in North America.
5.
go back to reference Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am J Trop Med Hyg. 2008;79:974–9.PubMed Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am J Trop Med Hyg. 2008;79:974–9.PubMed
6.
go back to reference Schweitzer BK, Kramer WL, Sambol AR, et al. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol. 2006;13:314–8.PubMedCrossRef Schweitzer BK, Kramer WL, Sambol AR, et al. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol. 2006;13:314–8.PubMedCrossRef
7.
go back to reference Centers for Disease Control (CDC). West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:281–4. Centers for Disease Control (CDC). West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:281–4.
8.
go back to reference Petersen LR, Epstein JS. Problem solved? West Nile virus and transfusion safety. N Engl J Med. 2005;353:516–7.PubMedCrossRef Petersen LR, Epstein JS. Problem solved? West Nile virus and transfusion safety. N Engl J Med. 2005;353:516–7.PubMedCrossRef
9.
go back to reference Centers for Disease Control (CDC). West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263–7. Centers for Disease Control (CDC). West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263–7.
10.
go back to reference O’Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile virus infection of pregnant women in the United States: 2003–2004. Pediatrics. 2006;117:e537–45.PubMedCrossRef O’Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile virus infection of pregnant women in the United States: 2003–2004. Pediatrics. 2006;117:e537–45.PubMedCrossRef
11.
go back to reference Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med. 2004;141:360–5.PubMed Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med. 2004;141:360–5.PubMed
12.
13.
go back to reference Sejvar JJ, Marfin AA. Manifestations of West Nile neuroinvasive disease. Rev Med Virol. 2006;16:209–24.PubMedCrossRef Sejvar JJ, Marfin AA. Manifestations of West Nile neuroinvasive disease. Rev Med Virol. 2006;16:209–24.PubMedCrossRef
14.
go back to reference Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181–94.PubMedCrossRef Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181–94.PubMedCrossRef
16.
go back to reference •• Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999–2007. Pediatrics. 2009;123:e1084-9. This is the most comprehensive summary of pediatric cases of WNV in the United States over the 9 years following the first US appearance of WNV. PubMedCrossRef •• Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999–2007. Pediatrics. 2009;123:e1084-9. This is the most comprehensive summary of pediatric cases of WNV in the United States over the 9 years following the first US appearance of WNV. PubMedCrossRef
17.
go back to reference Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr Opin Ophthalmol. 2004;15:537–40.PubMedCrossRef Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr Opin Ophthalmol. 2004;15:537–40.PubMedCrossRef
18.
go back to reference Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11:1021–7.PubMed Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11:1021–7.PubMed
19.
go back to reference Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300.PubMedCrossRef Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300.PubMedCrossRef
20.
go back to reference Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174–9.PubMed Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174–9.PubMed
21.
go back to reference Lindsey NP, Kuhn S, Campbell GL, Hayes EB. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis. 2008;8:35–9.PubMedCrossRef Lindsey NP, Kuhn S, Campbell GL, Hayes EB. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis. 2008;8:35–9.PubMedCrossRef
22.
go back to reference Caillouet KA, Michaels SR, Xiong X, et al. Increase in West Nile neuroinvasive disease after Hurricane Katrina. Emerg Infect Dis. 2008;14:804–7.PubMedCrossRef Caillouet KA, Michaels SR, Xiong X, et al. Increase in West Nile neuroinvasive disease after Hurricane Katrina. Emerg Infect Dis. 2008;14:804–7.PubMedCrossRef
23.
go back to reference Hayes EB, O’Leary DR. West Nile virus infection: a pediatric perspective. Pediatrics. 2004;113:1375–81.PubMedCrossRef Hayes EB, O’Leary DR. West Nile virus infection: a pediatric perspective. Pediatrics. 2004;113:1375–81.PubMedCrossRef
24.
go back to reference DeSalvo D, Roy-Chaudhury P, Peddi R, et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466–9.PubMedCrossRef DeSalvo D, Roy-Chaudhury P, Peddi R, et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466–9.PubMedCrossRef
25.
go back to reference Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61:1210–20.PubMedCrossRef Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61:1210–20.PubMedCrossRef
26.
go back to reference Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006;134:1325–32.PubMedCrossRef Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006;134:1325–32.PubMedCrossRef
27.
go back to reference Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010;24(2):223–8.PubMedCrossRef Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010;24(2):223–8.PubMedCrossRef
28.
go back to reference • Murray KO, Koers E, Baraniuk S, et al. Risk Factors for Encephalitis from West Nile Virus: a matched case-control study using hospitalized controls. Zoonoses Public Health 2009 Jan 17 (Epub ahead of print). This is a recent nested case-control study to determine potential risk factors for developing WNE by analysis of WNV cases hospitalized in Houston from 2002 to 2004. • Murray KO, Koers E, Baraniuk S, et al. Risk Factors for Encephalitis from West Nile Virus: a matched case-control study using hospitalized controls. Zoonoses Public Health 2009 Jan 17 (Epub ahead of print). This is a recent nested case-control study to determine potential risk factors for developing WNE by analysis of WNV cases hospitalized in Houston from 2002 to 2004.
29.
go back to reference Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.PubMed Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.PubMed
30.
go back to reference Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43:5873–5.PubMedCrossRef Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43:5873–5.PubMedCrossRef
31.
go back to reference Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol. 2001;39:4506–13.PubMedCrossRef Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol. 2001;39:4506–13.PubMedCrossRef
32.
go back to reference Tyler KL, Pape J, Goody RJ, et al. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66:361–5.PubMedCrossRef Tyler KL, Pape J, Goody RJ, et al. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66:361–5.PubMedCrossRef
33.
go back to reference Petzold A, Groves M, Leis AA, et al. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve. 2010;41:42–9.PubMedCrossRef Petzold A, Groves M, Leis AA, et al. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve. 2010;41:42–9.PubMedCrossRef
34.
go back to reference Brilla R, Block M, Geremia G, Wichter M. Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis. J Neurol Sci. 2004;220:37–40.PubMedCrossRef Brilla R, Block M, Geremia G, Wichter M. Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis. J Neurol Sci. 2004;220:37–40.PubMedCrossRef
35.
go back to reference Ali M, Safriel Y, Sohi J, et al. West Nile virus infection: MR imaging findings in the nervous system. AJNR Am J Neuroradiol. 2005;26:289–97.PubMed Ali M, Safriel Y, Sohi J, et al. West Nile virus infection: MR imaging findings in the nervous system. AJNR Am J Neuroradiol. 2005;26:289–97.PubMed
36.
go back to reference Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol. 2005;26:1986–95.PubMed Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol. 2005;26:1986–95.PubMed
38.
go back to reference Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J Neuropathol Exp Neurol. 2009;68:1061–72.PubMedCrossRef Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J Neuropathol Exp Neurol. 2009;68:1061–72.PubMedCrossRef
39.
go back to reference Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617–24.PubMedCrossRef Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617–24.PubMedCrossRef
40.
go back to reference Murray KO, Baraniuk S, Resnick M, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002–2004. Vector Borne Zoonotic Dis. 2008;8:167–74.PubMedCrossRef Murray KO, Baraniuk S, Resnick M, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002–2004. Vector Borne Zoonotic Dis. 2008;8:167–74.PubMedCrossRef
41.
go back to reference Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12:514–6.PubMed Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12:514–6.PubMed
42.
go back to reference Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol. 2008;2:477–99.PubMedCrossRef Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol. 2008;2:477–99.PubMedCrossRef
43.
go back to reference Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg Infect Dis. 2007;13:479–81.PubMedCrossRef Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg Infect Dis. 2007;13:479–81.PubMedCrossRef
44.
go back to reference Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis. 2006;12:1260–2.PubMed Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis. 2006;12:1260–2.PubMed
45.
go back to reference Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol. 2009 Jun 8:1–8 (Epub ahead of print). Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol. 2009 Jun 8:1–8 (Epub ahead of print).
46.
go back to reference •• Diamond MS. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 2009;5:e1000452. This is an up-to-date, concise review of current science providing insights into WNV and WNND pathogenesis, including host genetic factors and viral determinants. PubMedCrossRef •• Diamond MS. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 2009;5:e1000452. This is an up-to-date, concise review of current science providing insights into WNV and WNND pathogenesis, including host genetic factors and viral determinants. PubMedCrossRef
47.
go back to reference Brault AC, Huang CY, Langevin SA, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162–6.PubMedCrossRef Brault AC, Huang CY, Langevin SA, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162–6.PubMedCrossRef
48.
go back to reference Moudy RM, Zhang B, Shi PY, Kramer LD. West Nile virus envelope protein glycosylation is required for efficient viral transmission by Culex vectors. Virology. 2009;387:222–8.PubMedCrossRef Moudy RM, Zhang B, Shi PY, Kramer LD. West Nile virus envelope protein glycosylation is required for efficient viral transmission by Culex vectors. Virology. 2009;387:222–8.PubMedCrossRef
49.
go back to reference Beasley DW, Davis CT, Whiteman M, et al. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004;18:35–41.PubMed Beasley DW, Davis CT, Whiteman M, et al. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004;18:35–41.PubMed
50.
go back to reference Wicker JA, Whiteman MC, Beasley DW, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349:245–53.PubMedCrossRef Wicker JA, Whiteman MC, Beasley DW, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349:245–53.PubMedCrossRef
51.
go back to reference Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol. 2006;80:9349–60.PubMedCrossRef Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol. 2006;80:9349–60.PubMedCrossRef
52.
go back to reference Piazza P, McMurtrey CP, Lelic A, et al. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS ONE. 2010;5:e15343.PubMedCrossRef Piazza P, McMurtrey CP, Lelic A, et al. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS ONE. 2010;5:e15343.PubMedCrossRef
53.
go back to reference Lanteri MC, O’Brien KM, Purtha WE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest. 2009;119:3266–77.PubMed Lanteri MC, O’Brien KM, Purtha WE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest. 2009;119:3266–77.PubMed
54.
go back to reference Mansfield KL, Johnson N, Cosby SL, et al. Transcriptional upregulation of SOCS 1 and suppressors of cytokine signaling 3 mRNA in the absence of suppressors of cytokine signaling 2 mRNA after infection with West Nile virus or tick-borne encephalitis virus. Vector Borne Zoonotic Dis. 2010;10:649–53.PubMedCrossRef Mansfield KL, Johnson N, Cosby SL, et al. Transcriptional upregulation of SOCS 1 and suppressors of cytokine signaling 3 mRNA in the absence of suppressors of cytokine signaling 2 mRNA after infection with West Nile virus or tick-borne encephalitis virus. Vector Borne Zoonotic Dis. 2010;10:649–53.PubMedCrossRef
55.
go back to reference Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.PubMedCrossRef Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.PubMedCrossRef
56.
go back to reference Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.PubMedCrossRef Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.PubMedCrossRef
57.
go back to reference Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5:e1000321.PubMedCrossRef Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5:e1000321.PubMedCrossRef
58.
go back to reference •• Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83:214–27. This excellent, up-to-date review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, with particular focus on progress toward development of effective therapies. PubMedCrossRef •• Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83:214–27. This excellent, up-to-date review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, with particular focus on progress toward development of effective therapies. PubMedCrossRef
59.
go back to reference Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–8.PubMedCrossRef Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–8.PubMedCrossRef
60.
go back to reference Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005;79:13350–61.PubMedCrossRef Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005;79:13350–61.PubMedCrossRef
61.
go back to reference Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004;15:101–9.PubMed Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004;15:101–9.PubMed
63.
go back to reference Ben Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5–12.PubMedCrossRef Ben Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5–12.PubMedCrossRef
64.
go back to reference Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol. 2003;77:12941–9.PubMedCrossRef Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol. 2003;77:12941–9.PubMedCrossRef
65.
go back to reference Morrey JD, Siddharthan V, Wang H, et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol. 2008;14:152–63.PubMedCrossRef Morrey JD, Siddharthan V, Wang H, et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol. 2008;14:152–63.PubMedCrossRef
66.
go back to reference Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11:522–30.PubMedCrossRef Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11:522–30.PubMedCrossRef
67.
go back to reference Thompson BS, Moesker B, Smit JM, et al. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009;5:e1000453.PubMedCrossRef Thompson BS, Moesker B, Smit JM, et al. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009;5:e1000453.PubMedCrossRef
68.
go back to reference Vogt MR, Moesker B, Goudsmit J, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol. 2009;83:6494–507.PubMedCrossRef Vogt MR, Moesker B, Goudsmit J, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol. 2009;83:6494–507.PubMedCrossRef
69.
go back to reference Zhang S, Vogt MR, Oliphant T, et al. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis. 2009;200:202–5.PubMedCrossRef Zhang S, Vogt MR, Oliphant T, et al. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis. 2009;200:202–5.PubMedCrossRef
70.
go back to reference Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci USA. 2010;107:2419–24. Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci USA. 2010;107:2419–24.
71.
go back to reference Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol. 2005;79:4599–609.PubMedCrossRef Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol. 2005;79:4599–609.PubMedCrossRef
72.
go back to reference Bai F, Wang T, Pal U, et al. Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis. 2005;191:1148–54.PubMedCrossRef Bai F, Wang T, Pal U, et al. Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis. 2005;191:1148–54.PubMedCrossRef
73.
go back to reference Bai F, Town T, Pradhan D, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007;81:2047–55.PubMedCrossRef Bai F, Town T, Pradhan D, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007;81:2047–55.PubMedCrossRef
74.
go back to reference Chang J, Wang L, Ma D, et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother. 2009;53:1501–8.PubMedCrossRef Chang J, Wang L, Ma D, et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother. 2009;53:1501–8.PubMedCrossRef
Metadata
Title
West Nile Virus Neuroinvasive Disease
Author
Roberta L. DeBiasi
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 4/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0193-9

Other articles of this Issue 4/2011

Current Infectious Disease Reports 4/2011 Go to the issue

Clinical Trial Report

Synergy: A Cautionary Tale

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.